FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 573 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency MOST POPULAR PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer October 29, 2019 School Teacher’s Breast Cancer Journey Inspired Her to Move to Australia... February 17, 2020 Five Questions with…Jennifer. March 24, 2022 FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers August 4, 2023 Load more HOT NEWS Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line... Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ People with Cancer Say Access to Their Clinical Notes Is Valuable
